| Literature DB >> 24408320 |
Marcelo A Fernandez-Viña1, Tao Wang, Stephanie J Lee, Michael Haagenson, Mahmoud Aljurf, Medhat Askar, Minoo Battiwalla, Lee-Ann Baxter-Lowe, James Gajewski, Ann A Jakubowski, Susana Marino, Machteld Oudshoorn, Steven G E Marsh, Effie W Petersdorf, Kirk Schultz, E Victoria Turner, Edmund K Waller, Ann Woolfrey, John Umejiego, Stephen R Spellman, Michelle Setterholm.
Abstract
In subjects mismatched in the HLA alleles C*03:03/C*03:04 no allogeneic cytotoxic T-lymphocyte responses are detected in vitro. Hematopoietic stem cell transplantation (HSCT) with unrelated donors (UDs) showed no association between the HLA-C allele mismatches (CAMMs) and adverse outcomes; antigen mismatches at this and mismatches other HLA loci are deleterious. The absence of effect of the CAMM may have resulted from the predominance of the mismatch C*03:03/C*03:04. Patients with hematologic malignancies receiving UD HSCT matched in 8/8 and 7/8 HLA alleles were examined. Transplants mismatched in HLA-C antigens or mismatched in HLA-A, -B, or -DRB1 presented significant differences (P < .0001) in mortality (hazard ratio [HR] = 1.37, 1.30), disease-free survival (HR = 1.33, 1.27), treatment-related mortality (HR = 1.54, 1.54), and grade 3-4 acute graft-versus-host disease (HR = 1.49, 1.77) compared with the 8/8 group; transplants mismatched in other CAMMs had similar outcomes with HR ranging from 1.34 to 172 for these endpoints. The C*03:03/C*03:04 mismatched and the 8/8 matched groups had identical outcomes (HR ranging from 0.96-1.05). The previous finding that CAMMs do not associate with adverse outcomes is explained by the predominance (69%) of the mismatch C*03:03/03:04 in this group that is better tolerated than other HLA mismatches.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24408320 PMCID: PMC3931192 DOI: 10.1182/blood-2013-10-532671
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113